| Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|---|---|---|---|---|
Revenue | |||||
1,085 | 467 | 0 | 0 | - | - |
Research and development expenses | |||||
9,650 | 14,271 | 7,629 | 6,664 | 7,207 | 2,443 |
General and administrative expenses | |||||
3,799 | 3,078 | 3,246 | 2,478 | 7,355 | 694 |
Capital loss | |||||
- | - | - | - | 10 | 0 |
Total operating expenses | |||||
12,364 | 16,882 | 10,875 | 9,142 | 14,572 | 3,137 |
Financial expenses (income), net | |||||
65 | 35 | 253 | 40 | -2,912 | -6 |
Loss before income taxes | |||||
-12,299 | -16,847 | -10,622 | -9,102 | -17,484 | -3,143 |
Taxes on Income | |||||
0 | 106 | 0 | 1 | 1 | 6 |
Net loss | |||||
-12,299 | -16,953 | -10,622 | -9,103 | -17,485 | -3,149 |
Basic and diluted net loss per share from continuing operations (in dollars per share) | |||||
0.98 | 1.49 | 0.96 | 0.88 | 3.45 | 0.63 |
Weighted-average number of shares outstanding used in computing basic and diluted net loss per share | |||||
12,487 | 11,374 | 11,100 | 10,323 | 5,069 | 4,955 |